Martin Shkreli Calls New FDA CBER Head Vinay Prasad “Nuts” and Predicts Pharmaceutical Companies Will “Go Out Of Business”

This article does not constitute investment advice, and the author does not hold shares in any of the stocks referenced herein.

Martin Shkreli’s Resurgence

Once labeled as one of America’s most despised executives for drastically increasing the price of a life-saving medication, Martin Shkreli has resurfaced post-incarceration as a notable voice on social media platform X. His unexpected insights, particularly on pharmaceutical matters, have attracted a considerable following.

Critique of FDA Leadership

Recently, Shkreli has taken aim at the new director of the FDA’s Center for Biologics Evaluation and Research (CBER), Vinay Prasad. His pointed remarks come in the wake of Prasad’s vocal opposition to COVID-19 booster shots, where he raised questions about the regulatory process.

The only “emergency”America still faces with covid-19 is that regulators like Peter Marks are either incompetent or corrupt to authorize a booster without clinical, randomized data.https://t.co/EByJciOSGI

— Vinay Prasad MD MPH (@VPrasadMDMPH) August 22, 2024

Prasad’s Position on COVID-19 Vaccines

Dr. Vinay Prasad, a prominent oncologist, has made headlines for advocating for more rigorous randomized trials before updating COVID-19 vaccine booster recommendations, aiming to ensure public safety and effectiveness.

I have talked to the heads of almost every single one of big pharma in the last 72 hours and he has no idea what it’s like out there. NONE! And Prasad has NO IDEA what it’s like out there. My people have been in this game for 25 years and they’re LOSING THEIR JOBS and these firms…

— Martin Shkreli (@MartinShkreli) May 6, 2025

Shkreli’s Stark Warnings

Shkreli has not held back in his criticism, labeling Prasad as “nuts”and asserting that he lacks a realistic understanding of the pharmaceutical sector’s current challenges. He claims to have recently engaged with executives from major pharmaceutical companies, warning of looming layoffs and potential business failures.

This sentiment is echoed in the actions of notable firms like Bristol Myers Squibb, which revealed it would cut 516 jobs in April 2025, totaling 806 layoffs for the year, compounded by an earlier reduction of 2, 200 positions in 2024.

Industry Perspectives on Shkreli’s Comments

Supporters of Shkreli’s critique may view it as an endorsement of Prasad’s independence from corporate influences. Conversely, others might interpret his statements as a distress signal from an industry facing overwhelming pressure.

Your Thoughts Count

What are your views on Martin Shkreli’s commentary regarding Vinay Prasad’s appointment? Does a capitalist economy not dictate that the strongest companies endure while struggling ones fade away? Share your insights in the comments section below.

Source & Images